Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
企業コードPEN
会社名Penumbra Inc
上場日Sep 18, 2015
最高経営責任者「CEO」Mr. Adam Elsesser, J.D.
従業員数4500
証券種類Ordinary Share
決算期末Sep 18
本社所在地One Penumbra Place
都市ALAMEDA
証券取引所NYSE Consolidated
国United States of America
郵便番号94502
電話番号15109952486
ウェブサイトhttps://www.penumbrainc.com/
企業コードPEN
上場日Sep 18, 2015
最高経営責任者「CEO」Mr. Adam Elsesser, J.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし